PortfoliosLab logoPortfoliosLab logo
CTLP vs. HRMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CTLP vs. HRMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cantaloupe, Inc. (CTLP) and Harmony Biosciences Holdings, Inc. (HRMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CTLP achieves a 5.46% return, which is significantly higher than HRMY's -14.22% return.


CTLP

1D
0.00%
1M
0.09%
YTD
5.46%
6M
5.86%
1Y
28.00%
3Y*
18.56%
5Y*
0.22%
10Y*
9.60%

HRMY

1D
3.85%
1M
-1.50%
YTD
-14.22%
6M
-13.24%
1Y
-9.09%
3Y*
-3.02%
5Y*
-0.67%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CTLP vs. HRMY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
CTLP
Cantaloupe, Inc.
5.46%11.67%28.34%70.34%-51.01%-15.27%33.50%
HRMY
Harmony Biosciences Holdings, Inc.
-14.22%8.75%6.53%-41.38%29.22%17.95%-2.32%

Correlation

The correlation between CTLP and HRMY is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.23

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Aug 20, 2020

0.24

The correlation between CTLP and HRMY shifts across timeframes, from 0.13 (1 year) to 0.27 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS

CTLP:

$0.07

HRMY:

$2.48

PE Ratio

CTLP:

167.76

HRMY:

12.93

PEG Ratio

CTLP:

0.00

HRMY:

0.13

PS Ratio

CTLP:

1.93

HRMY:

2.09

Total Revenue (TTM)

CTLP:

$320.82M

HRMY:

$899.11M

Gross Profit (TTM)

CTLP:

$92.41M

HRMY:

$688.25M

EBITDA (TTM)

CTLP:

$24.24M

HRMY:

$221.74M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CTLP vs. HRMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CTLP
CTLP Risk / Return Rank: 8585
Overall Rank
CTLP Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
CTLP Sortino Ratio Rank: 8484
Sortino Ratio Rank
CTLP Omega Ratio Rank: 9292
Omega Ratio Rank
CTLP Calmar Ratio Rank: 8585
Calmar Ratio Rank
CTLP Martin Ratio Rank: 8686
Martin Ratio Rank

HRMY
HRMY Risk / Return Rank: 3131
Overall Rank
HRMY Sharpe Ratio Rank: 3131
Sharpe Ratio Rank
HRMY Sortino Ratio Rank: 2929
Sortino Ratio Rank
HRMY Omega Ratio Rank: 2929
Omega Ratio Rank
HRMY Calmar Ratio Rank: 3131
Calmar Ratio Rank
HRMY Martin Ratio Rank: 3232
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CTLP vs. HRMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cantaloupe, Inc. (CTLP) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CTLPHRMYDifference
Sharpe ratioReturn per unit of total volatility

+1.65

Sortino ratioReturn per unit of downside risk

+2.65

Omega ratioGain probability vs. loss probability

1.48

1.00

+0.48

Calmar ratioReturn relative to maximum drawdown

3.47

-0.26

+3.73

Martin ratioReturn relative to average drawdown

9.31

-0.49

+9.79

CTLP vs. HRMY - Sharpe Ratio Comparison

The current CTLP Sharpe Ratio is 1.43, which is higher than the HRMY Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of CTLP and HRMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CTLPHRMYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.43

-0.22

+1.65

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.00

-0.01

+0.02

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.16

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.22

-0.05

-0.18

Drawdowns

CTLP vs. HRMY - Drawdown Comparison

The maximum CTLP drawdown since its inception was -99.98%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for CTLP and HRMY.


Loading charts...

Drawdown Indicators


CTLPHRMYDifference

Max Drawdown

Largest peak-to-trough decline

-99.98%

-68.48%

-31.50%

Max Drawdown (1Y)

Largest decline over 1 year

-10.26%

-34.49%

+24.23%

Max Drawdown (3Y)

Largest decline over 3 years

-35.07%

-50.81%

+15.74%

Max Drawdown (5Y)

Largest decline over 5 years

-77.69%

-68.48%

-9.21%

Max Drawdown (10Y)

Largest decline over 10 years

-82.71%

Current Drawdown

Current decline from peak

-99.55%

-47.30%

-52.25%

Average Drawdown

Average peak-to-trough decline

-99.10%

-35.20%

-63.90%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.88%

18.69%

-14.81%

Volatility

CTLP vs. HRMY - Volatility Comparison

The current volatility for Cantaloupe, Inc. (CTLP) is 2.20%, while Harmony Biosciences Holdings, Inc. (HRMY) has a volatility of 10.05%. This indicates that CTLP experiences smaller price fluctuations and is considered to be less risky than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CTLPHRMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

2.20%

10.05%

-7.85%

Volatility (6M)

Calculated over the trailing 6-month period

7.90%

30.17%

-22.27%

Volatility (1Y)

Calculated over the trailing 1-year period

24.88%

41.40%

-16.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

45.27%

50.04%

-4.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

58.47%

52.40%

+6.07%

Dividends

CTLP vs. HRMY - Dividend Comparison

Neither CTLP nor HRMY has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CTLP vs. HRMY - Financials Comparison

This section allows you to compare key financial metrics between Cantaloupe, Inc. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


50.00M100.00M150.00M200.00M250.00M20222023202420252026
78.69M
215.39M
(CTLP) Total Revenue
(HRMY) Total Revenue
Values in USD except per share items

CTLP vs. HRMY - Profitability Comparison

The chart below illustrates the profitability comparison between Cantaloupe, Inc. and Harmony Biosciences Holdings, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
79.3%
Portfolio components
CTLP - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cantaloupe, Inc. reported a gross profit of 0.00 and revenue of 78.69M. Therefore, the gross margin over that period was 0.0%.

HRMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.

CTLP - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cantaloupe, Inc. reported an operating income of -767.00K and revenue of 78.69M, resulting in an operating margin of -1.0%.

HRMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.

CTLP - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cantaloupe, Inc. reported a net income of -2.16M and revenue of 78.69M, resulting in a net margin of -2.7%.

HRMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.


Frequently Asked Questions


CTLP and HRMY have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

HRMY has higher volatility (10.05%) compared to CTLP (2.20%). In terms of maximum drawdown, CTLP dropped -99.98% vs HRMY's -68.48%.

CTLP currently has the higher Sharpe Ratio (1.43 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CTLP and HRMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer